David M. Kurtz

10.3k total citations · 1 hit paper
112 papers, 2.9k citations indexed

About

David M. Kurtz is a scholar working on Cancer Research, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, David M. Kurtz has authored 112 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Cancer Research, 51 papers in Pathology and Forensic Medicine and 35 papers in Oncology. Recurrent topics in David M. Kurtz's work include Cancer Genomics and Diagnostics (58 papers), Lymphoma Diagnosis and Treatment (46 papers) and CAR-T cell therapy research (24 papers). David M. Kurtz is often cited by papers focused on Cancer Genomics and Diagnostics (58 papers), Lymphoma Diagnosis and Treatment (46 papers) and CAR-T cell therapy research (24 papers). David M. Kurtz collaborates with scholars based in United States, Germany and Switzerland. David M. Kurtz's co-authors include Jayant A. Talwalkar, Scott J. Schoenleber, Víctor M. Montori, Ash A. Alizadeh, Maximilian Diehn, Colin P. West, Florian Scherer, Jacob J. Chabon, Chih Long Liu and Aaron M. Newman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

David M. Kurtz

95 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrated digital error suppression for improved detection of circulating tumor DNA

2016 716 citations Aaron M. Newman, David M. Kurtz et al. profile →

Peers

David M. Kurtz

PFM

ONCOL

PRM

Sun‐Young Kong South Korea

Yohei Masugi Japan

Pierre‐Jean Lamy France

Bruno V. Sinn Germany

Gerald W. Prager Austria

Xavier Sagaert Belgium

Peter Vermeulen Belgium

Jun Gong United States

Filippo Pietrantonio Italy

Kenjiro Sawada Japan

Sun‐Young Kong South Korea

David M. Kurtz

683 ×0.6

1.4k ×1.6

416 ×0.6

PFM

1.3k ×1.9

ONCOL

498 ×1.0

PRM

Citations per year, relative to David M. Kurtz David M. Kurtz (= 1×) peers Sun‐Young Kong

Countries citing papers authored by David M. Kurtz

Since Specialization

Citations

This map shows the geographic impact of David M. Kurtz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Kurtz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Kurtz more than expected).

Fields of papers citing papers by David M. Kurtz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Kurtz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Kurtz. The network helps show where David M. Kurtz may publish in the future.

Co-authorship network of co-authors of David M. Kurtz

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Kurtz. A scholar is included among the top collaborators of David M. Kurtz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Kurtz. David M. Kurtz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Strati, Paolo, Lei Feng, Jason R. Westin, et al.. (2025). Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. Nature Communications. 16(1). 7300–7300.

Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2025). Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Journal of Clinical Oncology. 43(34). 3652–3661.

Kurtz, David M., et al.. (2024). Dry Heat Sterilization of a Pelleted, Natural Ingredient Rodent Diet. Journal of the American Association for Laboratory Animal Science. 63(4). 377–384.

Durán, George E., Sebastian Fernandez‐Pol, Shufeng Li, et al.. (2024). Genetic alteration of class I HLA in cutaneous T-cell lymphoma. Blood. 145(3). 311–324. 1 indexed citations

Cabel, Luc, David M. Kurtz, Daniel W. Ross, et al.. (2024). 293P Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq. Annals of Oncology. 35. S338–S338. 1 indexed citations

Goldstein, Jordan, Christopher Abbosh, Ash A. Alizadeh, Maximilian Diehn, & David M. Kurtz. (2024). Abstract 986: Mathematical modeling of ctDNA dynamics to predict utility of ultrasensitive MRD assays in early stage non-small cell lung cancer (NSCLC). Cancer Research. 84(6_Supplement). 986–986. 1 indexed citations

Goldstein, Jordan, Mark Roschewski, Won-Seog Kim, et al.. (2024). Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL. Blood. 144(Supplement 1). 651–651.

Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2023). MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS. Hematological Oncology. 41(S2). 177–179. 5 indexed citations

Schroers‐Martin, Joseph G., Jurik Mutter, Mohammad Shahrokh Esfahani, et al.. (2023). Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma. Blood. 142(Supplement 1). 528–528.

10.

Schroers‐Martin, Joseph G., Joanne Soo, Florian Scherer, et al.. (2023). Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors. Cancer Discovery. 13(6). 1310–1323. 23 indexed citations

11.

Nagy, Ákos, Gregory J. Hogan, Jacob J. Chabon, et al.. (2023). Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas. Blood. 142(Supplement 1). 1626–1626. 1 indexed citations

12.

Ahmed, Sairah, Matthew Mei, David M. Kurtz, et al.. (2023). Combined autologous CD30.CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study). Hematological Oncology. 41(S2). 524–525.

13.

Gunaratne, Ruwan, Matthew Schwede, Matthew S. Alkaitis, et al.. (2023). Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML). Blood. 142(Supplement 1). 4307–4307. 1 indexed citations

14.

Shree, Tanaya, Vishnu Shankar, Debra K. Czerwinski, et al.. (2022). CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity. Blood Cancer Discovery. 3(2). 95–102. 27 indexed citations

15.

Steen, Chloé B., Bogdan Luca, Mohammad Shahrokh Esfahani, et al.. (2021). The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 39(10). 1422–1437.e10. 149 indexed citations

16.

Sills, Robert C., G. Allan Johnson, Robert J. Anderson, et al.. (2020). Qualitative and Quantitative Neuropathology Approaches Using Magnetic Resonance Microscopy (Diffusion Tensor Imaging) and Stereology in a Hexachlorophene Model of Myelinopathy in Sprague-Dawley Rats. Toxicologic Pathology. 48(8). 965–980. 3 indexed citations

17.

Schroers‐Martin, Joseph G., Florian Scherer, Joanne Soo, et al.. (2017). Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis. Blood. 130. 308–308. 1 indexed citations

18.

Soo, Joanne, Florian Scherer, David M. Kurtz, et al.. (2017). Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens. Blood. 130. 1466. 1 indexed citations

19.

O’Neill, Brian Patrick, Mark E. Law, Paul A. Decker, et al.. (2008). Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course. Journal of Clinical Oncology. 26(29). 4814–4819. 78 indexed citations

20.

Kurtz, David M., Ravi Tolwani, & Philip A. Wood. (1998). Structural characterization of the mouse long-chain acyl-CoA dehydrogenase gene and 5′ regulatory region. Mammalian Genome. 9(5). 361–365. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact